Frankfurt - Delayed Quote EUR

Quia Pharma AB (publ) (99B0.F)

Compare
0.0010 -0.0001 (-9.09%)
At close: December 20 at 9:19:19 AM GMT+1
Loading Chart for 99B0.F
DELL
  • Previous Close 0.0011
  • Open 0.0010
  • Bid --
  • Ask --
  • Day's Range 0.0010 - 0.0010
  • 52 Week Range 0.0001 - 0.0153
  • Volume 1,000,000
  • Avg. Volume 63,076
  • Market Cap (intraday) 2.145M
  • Beta (5Y Monthly) 0.44
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0000
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Quia Pharma AB (publ) engages in the research, development, and commercialization of medicines based on Uni-Qleaver, a drug delivery platform. The company develops drugs through its pegylation technology platform. Its product pipeline includes QPG-1030 (pegylated teduglutide) for the treatment of short bowel syndrome, and QPG-1029 under pre-clinical development for stable plasma concentration, as well as antibody-drug conjugates being developed using the company's Uni-Qleaver technology-platform. The company was formerly known as QuiaPEG Pharmaceuticals Holding AB (publ) and changed its name to Quia Pharma AB (publ). Quia Pharma AB (publ) was founded in 2004 and is headquartered in Uppsala, Sweden.

www.quiapeg.com

3

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 99B0.F

View More

Performance Overview: 99B0.F

Trailing total returns as of 12/20/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

99B0.F
82.46%
OMX Stockholm 30 Index
3.19%

1-Year Return

99B0.F
87.01%
OMX Stockholm 30 Index
3.78%

3-Year Return

99B0.F
99.97%
OMX Stockholm 30 Index
7.32%

5-Year Return

99B0.F
99.99%
OMX Stockholm 30 Index
38.77%

Compare To: 99B0.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 99B0.F

View More

Valuation Measures

Annual
As of 12/20/2024
  • Market Cap

    2.23M

  • Enterprise Value

    2.00M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.77

  • Price/Book (mrq)

    0.49

  • Enterprise Value/Revenue

    9.77

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -277.59%

  • Return on Assets (ttm)

    -25.27%

  • Return on Equity (ttm)

    -63.90%

  • Revenue (ttm)

    4.99M

  • Net Income Avi to Common (ttm)

    -13.86M

  • Diluted EPS (ttm)

    -0.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.58M

  • Total Debt/Equity (mrq)

    9.59%

  • Levered Free Cash Flow (ttm)

    -27.09M

Research Analysis: 99B0.F

View More

Company Insights: 99B0.F

Research Reports: 99B0.F

View More